Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05211947 · ClinicalTrials.gov registry record · Phase 3
A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,356
- Enrollment target
NCT05211947: Clinical Trial Phase 3 study, sponsored by Boehringer Ingelheim.
NCT05211947 is a Phase 3 study that was terminated before completion, run by Boehringer Ingelheim. The registered enrollment target is 1,356 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (76% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05211947, a Phase 3 study, was terminated before completion, sponsored by Boehringer Ingelheim.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,356 participants
- Enrollment target
Study Summary
This study is open to adults with schizophrenia who took part in a previous CONNEX study (study 1346-0011, 1346-0012, or 1346-0013). The purpose of this study is to find out how well people with schizophrenia can tolerate a medicine called Iclepertin in the long term. Participants take Iclepertin as tablets once a day for 1 year. In addition, all participants take their normal medication for schizophrenia. Participants are in the study for a little more than 1 year. During this time, they visit the study site about 13 times and get about 9 phone calls from the study team. The doctors collect information on any health problems of the participants. Doctors also regularly check the participants' symptoms of schizophrenia.
Primary Outcome
Number of participants with treatment emergent adverse events.
Interventions
- DRUG Iclepertin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,356 participants |
| Start Date | 2022-03-21 |
| Est. Completion | 2025-03-18 |
| Phase | Phase 3 |
Why NCT05211947 stopped before completion
NCT05211947 is an interventional study that assigns participants to a tested intervention. Its 1,356 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (76% higher).
The record links to 0 conditions, and to 1 intervention - of which Iclepertin is the first listed.
NCT05211947 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05211947 about?
NCT05211947 is a clinical study titled "A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study". This study is open to adults with schizophrenia who took part in a previous CONNEX study (study 1346-0011, 1346-0012, or 1346-0013). The purpose of this study is to find out how well people with schizophrenia can tolerate a medicine called Iclepertin in the long term. Participants take Iclepertin a...
What is the current status of trial NCT05211947?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,356 participants. The study started on 2022-03-21. Estimated completion is 2025-03-18.
What interventions are being tested in trial NCT05211947?
The interventions under investigation include: Iclepertin (DRUG).
Who is sponsoring clinical trial NCT05211947?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05211947's enrollment target sits among peer trials
1,356 181st of 2000 higher than 1,820 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05245227 · 1,358 participants · Phase 3
Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage
- NCT06318169 · 1,350 participants · Phase 3
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- NCT06605404 · 1,350 participants
Pan-tumor MRD Study
- NCT06806163 · 1,350 participants · NA
Machine-Learning Prediction and Reducing Overdoses With EHR Nudges
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI